Cannabis use patterns and association with hyperemesis: A comprehensive review.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analysis
PubMed 39164887 · doi:10.1111/nmo.14895
What was done
This narrative review synthesized literature on cannabis use patterns in the United States, clinical characteristics of cyclic vomiting syndrome (CVS) and cannabinoid hyperemesis syndrome (CHS), diagnostic distinctions, and management strategies.
What was found
Forty to eighty percent of CVS patients report using cannabis products to alleviate nausea, vomiting, and stress. CHS is associated with longstanding, high-dose cannabis use, with most patients reporting daily or near-daily use for more than 2 years. Compulsive hot-water bathing is reported by most CHS patients, but is not specific to the condition as it also occurs in about half of CVS patients. Cannabis abstinence is the primary management strategy for CHS. The abstract provides no other quantitative metrics.
Why it matters
With increasing availability of high-potency cannabis, distinguishing CHS from CVS is essential for preventing recurrent healthcare utilization and focusing treatment on sustained cannabis cessation.
Limits
This is a narrative review rather than a systematic review, with no search methodology, inclusion criteria, or total participant sample size reported in the abstract. Quantitative data on cessation success rates and long-term outcomes were not provided.
Cited by
- supports Chronic cannabis exposure can lead to cannabinoid hyperemesis syndrome, causing cyclical vomiting despite initial anti-emetic effects.